Table 2 Patient and tumour characteristics and response by whether patient’s tumour assessed by agilent microarray
Included phase I/II | Schedule A N with banked tumour = 46 | Schedule B N with banked tumour = 46 | |||||||
|---|---|---|---|---|---|---|---|---|---|
Yes (N = 41) | No (N = 5) | Total (N = 46) | P value1 | Yes (N = 35) | No (N = 11) | Total (N = 46) | P value1 | ||
Clinical N stage | N1 | 17 | 1 | 18 | 8 | 2 | 10 | ||
N2 | 15 | 3 | 18 | 24 | 5 | 29 | |||
N3 | 3 | 0 | 3 | 2 | 3 | 5 | |||
NX | 6 | 1 | 7 | 1 | 0 | 1 | |||
N0 | 0 | 0 | 0 | 0.6983 | 0 | 1 | 1 | 0.1074 | |
Clinical T stage | T2 | 2 | 0 | 2 | 1 | 0 | 1 | ||
T3 | 13 | 1 | 14 | 18 | 5 | 23 | |||
T4 | 26 | 4 | 30 | 16 | 4 | 20 | |||
T1 | 0 | 0 | 0 | 0 | 1 | 1 | |||
TX | 0 | 0 | 0 | 1.0000 | 0 | 1 | 1 | 0.2185 | |
Age | Median | 48.5 | 47.8 | 41.8 | 45.4 | ||||
Range | (27.4, 72.3) | (44.1, 72.2) | 0.3061 | (28.2, 65.2) | (27.5, 60.1) | 0.7088 | |||
ER | Median | 40 | 100 | 0 | 100 | ||||
Range | (0, 100) | (0, 100) | 0.3909 | (0, 100) | (0, 100) | 0.1919 | |||
PR | Median | 0 | 60 | 0 | 100 | ||||
Range | (0, 100) | (0, 100) | 0.04134 | (0, 100) | (0, 100) | 0.01362 | |||
Her2 | Median | 0 | 0 | 0 | 0 | ||||
Range | (0, 100) | (0, 0) | 0.06909 | (0, 100) | (0, 0) | 0.5997 | |||
Topo2 | Median | 70 | 90 | 80 | 100 | ||||
Range | (0, 100) | (0, 100) | 0.4537 | (0, 100) | (1, 90) | 0.1411 | |||
% tumour extent | Median | 100 | 90 | 85 | 80 | ||||
Range | (40, 100) | (60, 100) | 0.2862 | (0, 100) | (1, 100) | 0.9887 | |||